About MHC class I polypeptide-related sequence B
MHC class I polypeptide-related sequence B (MICB) is a protein
from Homo sapiens identified by UniProt accession
Q29980, 383 residues long.
MolForge cross-references it against 0 known binders and
240 disease associations.
Target properties
| Protein name | MHC class I polypeptide-related sequence B |
| UniProt accession | Q29980 |
| Gene | MICB |
| Organism | Homo sapiens |
| Length | 383 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (240)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.39
- rheumatoid arthritis · score 0.38
- myositis · score 0.32
- neurodegenerative disease · score 0.29
- mean corpuscular hemoglobin · score 0.28
- asthma · score 0.28
- triglyceride measurement · score 0.27
- MHC class I polypeptide-related sequence B measurement · score 0.27
- type 2 diabetes mellitus · score 0.25
- Dengue Hemorrhagic Fever · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q29980-F1 | alphafold | PREDICTED | 77.97 | — |
Amino-acid sequence (383 residues)
MGLGRVLLFL AVAFPFAPPA AAAEPHSLRY NLMVLSQDGS VQSGFLAEGH LDGQPFLRYD RQKRRAKPQG QWAENVLGAK TWDTETEDLT ENGQDLRRTL THIKDQKGGL HSLQEIRVCE IHEDSSTRGS RHFYYDGELF LSQNLETQES TVPQSSRAQT LAMNVTNFWK EDAMKTKTHY RAMQADCLQK LQRYLKSGVA IRRTVPPMVN VTCSEVSEGN ITVTCRASSF YPRNITLTWR QDGVSLSHNT QQWGDVLPDG NGTYQTWVAT RIRQGEEQRF TCYMEHSGNH GTHPVPSGKA LVLQSQRTDF PYVSAAMPCF VIIIILCVPC CKKKTSAAEG PELVSLQVLD QHPVGTGDHR DAAQLGFQPL MSATGSTGST EGT
Explore MHC class I polypeptide-related sequence B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets